Remunity, an innovative pump for Remodulin (treprostinil) to treat adults with pulmonary arterial hypertension (PAH), has launched commercial sales, according to the device’s developer, United Therapeutics. The Remunity system allows constant subcutaneous (under-the-skin) delivery of Remodulin (treprostinil). The therapy mimics the effects of prostacyclin, a natural vasodilator that helps blood vessels widen, improving blood flow and preventing blockage in arteries. “We are excited to bring to market the first subcutaneous pump designed specifically for PAH patients,”…

You must be logged in to read/download the full post.